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Abstract
Background: Malawi has the highest cervical cancer incidence and mortality in the world with age-standardized
rate (ASR) of 75.9 and 49.8 per 100,000 population respectively. In response, Ministry of Health established a cervical
cancer screening programme using visual inspection with acetic acid (VIA) and treatment of precancerous lesions
with cryotherapy. This paper highlights the roll out, integration with family planning services and HIV ART
Programme, uptake and challenges of VIA and Cryotherapy programme.
Methods: We analyzed program data, supportive supervision, quarterly and annual reports from the National
Cervical Cancer Control Program. We evaluated the uptake and challenges of screening services by age, HIV
serostatus and trends over a five year period (2011–2015).
Results: Between 2011 and 2015, number of cervical cancer screening sites, number of women screened and
coverage per annum increased from 75 to 130, 15,331 to 49,301 and 9.3 % to 26.5 % respectively. In this five year
period, a total of 145,015 women were screened. Of these, 7,349 (5.1 %) and 6,289 (4.3 %) were VIA positive and
suspect cancer respectively. Overall 13,638 (9.4 %) were detected to be VIA positive or had suspect cancer. Of the
48,588 women with known age screened in 2015; 13,642 (28.1 %), 27,275 (56.1 %) and 7,671 (15.8 %) were aged 29 or
less, 30–45, 46 years or more. Among 39,101 women with data on HIV serostatus; 21,546 (55.1 %) were HIV negative,
6,209 (15.9 %) were HIV positive and 11, 346 (29.0 %) status was unknown. VIA positivity rate and prevalence of suspect
cancer were significantly higher in HIV positive than HIV negative women (8.8 % vs 5.0 %, 6.4 % vs 3.0 %); in women
aged 30–45 years than women aged 29 years or less (5.6 % vs 2.3 %, 2.6 % vs 1.2 %) respectively, all p <0.05). The main
challenge of the programme was failure to treat VIA positive women eligible for cryotherapy. Over the five year period,
the programme only treated 1,001 (43.3 %) out of 2,311 eligible women and only 266 (31.8 %) of the 836 women with
large lesion or suspect cancer who were referred, received the health care at the referral centre. The reasons for failure
to provide cryotherapy treatment were stock out of gas, faulty/broken cryotherapy machine (usually connectors or
probes) or no cryotherapy machine at all in the whole district. For women with large lesion or suspect cancer; lack of
loop electrosurgical excision procedure (LEEP) machine or inadequate gynaecologists at the referral centre, were the
major reasons. Cancer radiotherapy services were not available in Malawi.
Conclusions: This study provided data on VIA positivity rate, prevalence of suspect cancer, failure rate of cryotherapy
and challenges in the provision of cryotherapy and LEEP treatment in Malawi. These data could be used as baseline for
monitoring and evaluation of Human Papillomavirus (HPV) vaccination programme which the country introduced in
2013, the linkage of cervical cancer screening and women on HIV ART and the long term effect of ART, voluntary male
medical circumcision on the prevalence and incidence of cervical cancer.
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Background
Malawi has the highest cervical cancer incidence and
mortality in the world with age-standardized rate (ASR)
of 75.9 and 49.8 per 100,000 population respectively [1].
Cervical Cancer accounts for 45.4 % of all cancers in
women and the trend is increasing [2]. Every year, over
2,300 women develop cervical cancer and over 1,600 die
from the disease [3]. The median survival time from the
time of diagnosis is 10 months and 5-year survival rate
is 2.9 % [4]. High prevalence of HIV (10.6 %), human
papilloma virus (33.6 %), inadequate screening and treat-
ment services for precancerous lesions, late diagnosis,
limited access to timely, standard treatment of cancer
and palliative care are the main risk factors for high cer-
vical cancer incidence and mortality [5–8].
In response to high burden of cervical cancer, the
Malawi Ministry of Health, through Sexual and
Reproductive Health Directorate is implementing
human papillomavirus (HPV) vaccination pilot pro-
ject and screen-and-treat programme using visual
inspection with acetic acid (VIA) and cryotherapy.
The cervical cancer screening programme started in
2004 as a pilot project in Mulanje district. The
programme is integrated with family planning ser-
vices and targets women aged 30–45 years and
women on HIV ART. HIV negative women are
screened once every five years while HIV positive
are screened once every 2–3 years. By 2011 the
programme was scaled up to all central and district
hospitals, most mission hospitals and some health
centres and private hospitals. There were over 130
VIA, 32 cryotherapy, 11 cold coagulation and 3
loop electrosurgical excision procedure (LEEP) sites
in public health facilities across the country [9].
Malawi is one of the few countries in east and southern
Africa with high burden of cervical cancer that have rolled
out screen-and- treat programme nationally. However
data on successes and challenges of the Malawi na-
tional programme have not been documented before.
This paper therefore aims to contribute in filling the
information gap on the uptake, outcome by age and
HIV sero-status, overall cure rate and challenges of




This was a retrospective cohort study of women at-
tending cervical cancer screening sites for initial visit,
sub-sequent visit and follow up. Analysis of the na-
tional cervical cancer control programme database
and reports of national, zonal, and district supportive
supervision and annual programme review meetings
for the period 2011–2015 was conducted.
Data management
Data was entered in Microsoft excel® and exported to
SPSS version 20 for analysis. Some of the variables ana-
lyzed were: trend in the number of women screened
over 5-year period, VIA positivity rate and prevalence of
suspect cancer among women screened by age and HIV
status, proportion of women who actually received cryo-
therapy among those who were eligible, loss to follow up
among women eligible for cryotherapy and overall cure
rate at 1- year for cryotherapy. According to Malawi
National Statistics Office (NSO) population figures,
women aged 30–45 years (the target group) constitute
6.74 % of the total population [5]. The target for the
national cervical cancer programme is to screen at
least 80 % of the target population over five years.
Therefore the annual target was calculated as total
population multiplied by 0.0674 multiplied by 0.8 di-
vided by 5. The annual coverage (%) was therefore
calculated by dividing the total number of women
screened per year by the annual target multiplied by
100. Confidence intervals (CI) for proportion were
calculated using the formula p = p ± C√p(1-p)/n where p
is the given proportion whose CI needs to be calculated, C
is the coefficient, at 95 % CI, C = 1.96, n = number of
participants. The results were statistically significant if
Chi-square p < 0.05 or there was no overlap between two
CIs of comparing groups; HIV negative vs HIV positive,
age 30–45 years vs age ≤29 years, or ≥46 years. All ana-
lyses were made at 95 % confidence level.
Results
Number of cervical cancer screening and treatments sites
and providers
As of 31 December 2015, there were a total of 130
(an increase from 75 in 2011) VIA and 1 Pap smear
(Malamulo Makwasa Hospital) public sites that were
conducting cervical cancer screening countrywide.
The screening services were available (at least at dis-
trict hospital) in all the districts except one (Likoma
Island). There were 32 established cryotherapy sites.
Of these 10 were not functional because the machine
was faulty, mainly the connectors or the probes were
broken (7 sites) or lack of gas (3 sites). Four cryo-
therapy sites which were not functional (Rumphi,
Nkhatabay, Mulanje and Phalombe) were in the dis-
tricts where there was no any other site to treat VIA
positive eligible cases and women were referred to
another district. One district (Ntchisi) never had cryo-
therapy although it was providing screening services.
In addition to 22 functional cryotherapy sites, they
were 11 cold (thermo) coagulation sites which were
introduced recently (2013–2015) as a new treatment
method for pre-cancerous cervical cancer lesions. There
were a total of 395 VIA and cryotherapy providers who
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were trained during the period 2011–2015. Of these, 276
(69.9 %) were active and providing the services. On aver-
age therefore, there were 2 (276/130) active providers per
VIA site.
Number of women screened and their outcomes
In 2015, at total of 49,301 women were screened for cer-
vical cancer countrywide. Of these, 44,951 (91.2 %) were
initial, 1,487 (3.0 %) were one year follow up after cryo-
therapy and 2,857 (5.8 %) was sub-subsequent visit at
five years after VIA negative result at the initial screen-
ing. In total there were 2,311 (4.7 %), 2,082 (4.6 %), 105
(7.1 %) and 124 (4.3 %) VIA positive women among all
women screened, initial, one year follow up and sub-
sequent respectively. Of the 2,311 VIA positive women
who were eligible for cryotherapy, only 1,001 (43.3 %)
received cryotherapy. Among 1,001 cryotherapy con-
ducted, 562 (56.1 %) were done immediately (screen-
and-treat) 439 (43.9 %) were post-postponed and done
weeks or months later. Over 500 cryotherapy clients
who were post-postponed were never done. Lack of
cryotherapy machine, gas or faulty machine were the
common reasons for failure to treat VIA positive eligible
women. Of the 836 women who were referred to an-
other facility for cryotherapy or large lesion, only 266
(31.8 %) reported back to the facilities that referred them
after receiving treatment at the referral hospital. The
prevalence of suspect cancer among initial was 1,665
(3.7 %). There were no suspect cancer cases among one
year follow and sub-sequent visits.
Number of women screened by age and HIV serostatus
Of the 48,588 women with known age, 13,642 (28.1 %),
27,275 (56.1 %) and 7,671 (15.8 %) were aged 29 or less,
30–45, 46 years or more respectively. VIA positivity rate
was: 2.3 %, 5.6 % and 5.2 % while prevalence of suspect
cancer was 1.2 %, 2.6 % and 11.9 % respectively. Statisti-
cally, VIA positivity rate was significantly lower in
women aged 29 years or less and prevalence of suspect
cancer was higher in women aged 46 years or more
compared to women aged 30–45 years, all p < 0.05.
Among 39,101 women with data on HIV sero-status,
21,546 (55.1 %) were HIV negative, 6,209 (15.9 %) were
positive and 11,346 (29.0 %) the status was unknown.
Prevalence of VIA positivity and suspect cancer was
higher in HIV positive than HIV negative women, 8.8 %
vs 5.0 %, 6.4 % vs 3.0 % respectively, all p < 0.05
(Table 1).
Trends in cervical screening 2011–2015
Number women screened for cervical cancer increased
by year from 15,331 in 2011 to 49,301 in 2015. Coverage
of the eligible population (women aged 30–45 years,
6.74 % of total population, programme target 80 % to be
screened in 5 years) increased from 9.3 % in 2011 to
26.5 % by the end of 2015. A total of 145,015 women
were screened of whom 5.1 % and 4.3 % were VIA posi-
tive, had suspect cancer respectively. Only 40.4 % of
7,349 VIA positive women who were eligible for cryo-
therapy were actually treated. Positivity rate of VIA and
prevalence of suspect cancer remained around 5 % and
4 % respectively (Table 2).
Discussion
This was the first study in Malawi and one of the few
studies from countries in east and southern Africa where
the burden of cervical cancer is high, that has provided
comprehensive data on the roll out, successes and chal-
lenges of the cervical cancer screening and treatment of
pre-cancerous lesions. The study has documented that
Malawi successfully scaled up cervical cancer screening
services using visual inspection with acetic acid (VIA).
In the period 2011–2015, the number of cervical cancer
screening sites, number of women screened and cover-
age per annum increased from 75–130, 15,331–49,301
and 9.3–26.5 % respectively. A total of 145,015 women
were screened for at least once. Cervical cancer screen-
ing, even when done once, reduces the burden of cer-
vical cancer mortality. It is estimated that in countries
with high burden of HIV and cervical cancer, one-time
cervical cancer screening prevents one death for every
202 women screened [10, 11]. Based on this estimate, at
least 718 deaths due to cervical cancer were therefore
averted.
This study has also demonstrated that the VIA positiv-
ity rate and cryotherapy failure rate were similar to those
reported in Tanzania, Mozambique and systematic re-
views [12–16] but lower to what was reported in Zambia
and Kenya where VIA positivity rates were 17–20 %
[17–19]. Majority of women in Zambian and Kenyan
studies were HIV positive and therefore this could ex-
plain the high positivity rate.
It is well documented that HIV-positive women, com-
pared to HIV negative women, women aged 30–45 years
compared to women aged 29 years have a higher preva-
lence of cervical precancerous lesions as well as a faster
progression of these lesions to invasive cancer [20]. This
study was in agreement with these findings. VIA positiv-
ity rate and prevalence of suspect cancer were signifi-
cantly higher in HIV positive than HIV negative women
(8.8 % vs 5.0 %, 6.4 % vs 3.0 %) in women aged 30–45
years than women aged 29 years or less (5.6 % vs 2.3 %,
2.6 % vs 1.2 %) respectively, all p <0.05).
However, despite the aforementioned successes of the
Malawi National Cervical Cancer Screening Programme,
the programme faced a number of challenges. The main
challenge was failure to treat VIA positive women eli-
gible for cryotherapy. Over the five year period, the
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programme only treated 1,001 (43.3 %) out of 2,311 eli-
gible women. The problem was even worse for women
with large lesions or suspect cancer who were referred
to central hospitals for further assessment and manage-
ment. Of the 836 women who were referred, only 266
(31.8 %) received the service at the referral centre. The
main reasons for failure to provide cryotherapy treat-
ment were stock out of gas, faulty/broken cryotherapy
machine (usually connectors or probe) or no cryother-
apy machine at all in the whole district. For women with
large lesions or suspect cancer; lack of LEEP machine or
inadequate gynaecologists at the central hospitals, were
the major reasons. Cancer radiotherapy services were
not available in Malawi. Similar health system, equip-
ment and referral challenges were documented in
Mozambique and Kenya [13, 19]. This study therefore
contributed in documenting evidence on the challenges
faced in the provision of cryotherapy treatment although
it is considered to be affordable, effective and recom-
mended for resource- poor countries by WHO. In
Malawi, cryotherapy had a high running cost (gas, con-
nectors and probes) and districts were failing to sustain
the service. The three year experience from the 11 sites
that were providing cold (thermo) coagulation showed
that cold coagulation had no problems, low running
cost, easy to use by nurses and all eligible women re-
ceived the treatment [21]. All public hospitals have rela-
tively stable electricity and therefore cold coagulation
may be the way forward to high running cost of cryo-
therapy treatment in a resource- poor setting [22].
The other challenge that the programme experienced
was the high (32 %) loss to follow for a repeat cryother-
apy at one year follow up among women who tested
VIA positive and were done cryotherapy. With cryother-
apy failure rate of 7 %, it would be important to provide
evidence- informed counseling and strategies to reduce
the loss to follow up. High loss to follow up was also re-
ported in Kenya [19]. High staff turnover, though not pe-
culiar to this programme but a general problem in
ministry of health, was another challenge where up to
30 % of health workers that were trained were no longer
providing the cervical cancer screening services.
Lastly, although coverage of women screened for cer-
vical cancer per annum increased from 9 % in 2011 to
Table 1 Characteristics and outcome of women screened in 2015 by age and HIV status
Total VIA positive Suspect cancer VIA positive or suspect cancer
n % n % 95 % CI n % 95 % CI n % 95 % CI
Age (years):
≤ 29 13,642 28.1 307 2.3* 1.4-3.2 163 1.2* 0.3-2.1 470 3.4* 2.6-4.2
30-45 27,275 56.1 1,540 5.6 (ref) 5.0-6.2 710 2.6 (ref) 2.0-3.2 2,250 8.2 (ref) 7.6-8.8
≥ 46 7,671 15.8 399 5.2 4.1-6.3 910 11.9* 10.8-13.0 1,309 17.1* 16.1-18.1
All with known age 48,588 100.0 2,246 4.6 4.2-5.0 1,783 3.7 3.3-4.1 4,029 8.3 7.9-8.7
HIV status:
Negative 21,546 55.1 1,088 5.0 (ref) 4.3-5.7 638 3.0 (ref) 2.3-3.7 1,726 8.0 (ref) 7.3-8.7
Positive 6,209 15.9 546 8.8* 7.6-10.0 399 6.4* 5.2-7.6 945 15.2* 14.0-16.4
Unknown 11,346 29.0 558 4.9 4.0-5.8 520 4.6* 3.7-5.5 1,078 9.5* 8.6-10.4
All with HIV status data 39,101 100.0 2,192 5.6 5.1-6.1 1,557 4.0 3.5-4.5 3,749 9.6 9.1-10.1
CI = confidence interval, n = number of women in the group, VIA = visual inspection with acetic acid, % = percentage, ref = reference, * = statistically
significant, p < 0.05
Table 2 Trends in cervical screening in Malawi 2011-2015




Number of women with VIA positive
treated with cryo or cold coagulation
Number of women
with suspect cancer
n % coveragea n % n % n %
2011 164,145 15,331 9.3 894 5.8 388 43.4 798 5.2
2012 169,350 22,400 13.2 1,069 4.8 400 37.4 1,098 4.9
2013 174,735 20,490 11.7 1,447 7.1 528 36.5 1,294 6.3
2014 180,306 37,493 20.8 1,628 4.3 655 40.2 1,434 3.8
2015 186,069 49,301 26.5 2,311 4.7 1,001 43.3 1,665 3.4
Total 145,015 - 7,349 5.1 2,972 40.4 6,289 4.3
Cryo = Cryotherapy, n = number of women in the group, VIA = visual inspection with acetic acid, % = percentage
aAnnual coverage (%) = Number of women screened in a year/Annual target ×100
Annual target = Total population × 0.0674 × 0.8/ 5
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27 % in 2015, it was still far below the programme target
of 80 %. Concerted efforts by government, development
partners and non-governmental organizations to address
the above named challenges may improve the coverage.
Limitations of the study
This study made use of the available programme health fa-
cility data and reports on cervical cancer screening and
treatment. The use of health facility data has its own limi-
tations, such as incompleteness and bias in the sense that
the information is obtained only from people who came
to health facilities or clinics. These limitations were not
peculiar to this study but would affect any other study that
uses facility data. Nonetheless, this comprehensive docu-
mentation has contributed in providing information on
the successes and challenges of VIA and cryotherapy
programme in a resource-poor setting.
Conclusions
This study has provided data on VIA positivity rate,
prevalence of suspect cancer, failure rate of cryotherapy
and challenges in the provision of cryotherapy and LEEP
treatment in Malawi. These data could be used as baseline
for monitoring and evaluation of Human Papillomavirus
(HPV) vaccination programme which was introduced in
2013, the linkage of cervical cancer screening and women
on HIV ART and the long term effect of ART, voluntary
male medical circumcision or a combination of these pro-
grammes on the prevalence and incidence of cervical
cancer. Concerted efforts by government, development
partners and non-governmental organizations to address
the challenges faced by the programme may improve the
coverage. Because of high running cost of cryotherapy,
cold coagulation could be considered as an alternative
treatment method in Malawi, a poor country in central-
southern Africa.
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